A monoclonal antibody (mAb) targeting human PCNA, 14-25-9, has been shown to effectively recognize cell surface PCNA on both solid and leukemic cancer cell lines, as well as tumor cells derived from patient-derived xenografts. This evidence concerns the gene PCNA and neoplasm.